To address the lack of competition between generic and off-patent brand-name drugs, the FDA issued new guidance to encourage generic entry into the marketplace.
The guidelines outline a “novel pathway that provides incentives for developing generic versions of drugs that currently face little or no competition,” the agency noted in a statement.